The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
Circle Pharma and Verismo feature in coveted sessions.
